{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:00:38Z","timestamp":1789203638904,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"crossref","award":["E-26\/110.238\/2014"],"award-info":[{"award-number":["E-26\/110.238\/2014"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["312654\/2013-8"],"award-info":[{"award-number":["312654\/2013-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004933","name":"Instituto Nacional de Ci\u00eancia e Tecnologia","doi-asserted-by":"crossref","award":["573806\/2008-0"],"award-info":[{"award-number":["573806\/2008-0"]}],"id":[{"id":"10.13039\/501100004933","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Programa de Oncobiologia"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.leukres.2016.10.005","type":"journal-article","created":{"date-parts":[[2016,10,16]],"date-time":"2016-10-16T05:15:43Z","timestamp":1476594943000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice"],"prefix":"10.1016","volume":"51","author":[{"given":"Flavia","family":"da Cunha Vasconcelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Antonio","family":"Mauricio Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Moellman-Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Luiz","family":"Mencalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana Zalcberg","family":"Renault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Mary","family":"Rumjanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Ciuvalschi","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"October\u2013December; 5\u20136","key":"10.1016\/j.leukres.2016.10.005_bib0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","article-title":"The role of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"18","author":"Kujawski","year":"2007","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.leukres.2016.10.005_bib0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2008.1.419","article-title":"Milestones and monitoring in patients with CML treated with imatinib","author":"Deininger","year":"2008","journal-title":"Hematol. Am. Soc. Hematol. Educ. Prog."},{"issue":"June 6","key":"10.1016\/j.leukres.2016.10.005_bib0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"February 1","key":"10.1016\/j.leukres.2016.10.005_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.seminoncol.2011.11.002","article-title":"Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression","volume":"39","author":"Ernst","year":"2012","journal-title":"Semin Oncol."},{"issue":"March 6","key":"10.1016\/j.leukres.2016.10.005_bib0025","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"issue":"December 12","key":"10.1016\/j.leukres.2016.10.005_bib0030","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"November 104(9)","key":"10.1016\/j.leukres.2016.10.005_bib0035","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2drug pump.Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2drug pump","volume":"1","author":"Burger","year":"2004","journal-title":"Blood"},{"issue":"Suppl. 2 April","key":"10.1016\/j.leukres.2016.10.005_bib0040","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann. Hematol."},{"issue":"April 4","key":"10.1016\/j.leukres.2016.10.005_bib0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in good-risk chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"December (23)","key":"10.1016\/j.leukres.2016.10.005_bib0050","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"December 12","key":"10.1016\/j.leukres.2016.10.005_bib0055","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"issue":"September 9","key":"10.1016\/j.leukres.2016.10.005_bib0060","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"issue":"April 29(12)","key":"10.1016\/j.leukres.2016.10.005_bib0065","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800mg\/d versus 400mg\/d versus 400mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"20","author":"Hehlmann","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"May 10","key":"10.1016\/j.leukres.2016.10.005_bib0070","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2016.10.005_bib0075","unstructured":"Minist\u00e9rio da Sa\u00fade. Portaria SAS no 347 de 23 de junho de 2008. Protocolo e Diretrizes Terap\u00eauticas para o tratamento da Leucemia Miel\u00f3ide Cr\u00f4nica. Di\u00e1rio Oficial da Uni\u00e3o, no 120, de 25 de julho de 2008, se\u00e7\u00e3o 1, p\u00e1gina 54. Brasilia; 2008."},{"issue":"July 1","key":"10.1016\/j.leukres.2016.10.005_bib0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"August 6","key":"10.1016\/j.leukres.2016.10.005_bib0085","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"December 12","key":"10.1016\/j.leukres.2016.10.005_bib0090","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.leukres.2013.09.021","article-title":"Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients","volume":"37","author":"Vasconcelos","year":"2013","journal-title":"Leuk. Res."},{"issue":"May (3)","key":"10.1016\/j.leukres.2016.10.005_bib0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cyto.b.20580","article-title":"Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients","volume":"80","author":"Vasconcelos","year":"2011","journal-title":"Cytometry B Clin. Cytom."},{"issue":"6","key":"10.1016\/j.leukres.2016.10.005_bib0100","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"issue":"March 3","key":"10.1016\/j.leukres.2016.10.005_bib0105","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3324\/haematol.2013.095158","article-title":"Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy","volume":"99","author":"Etienne","year":"2014","journal-title":"Haematologica"},{"issue":"August 7","key":"10.1016\/j.leukres.2016.10.005_bib0110","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry","volume":"122","author":"H\u00f6glund","year":"2013","journal-title":"Blood"},{"issue":"October 10","key":"10.1016\/j.leukres.2016.10.005_bib0115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.clml.2015.06.006","article-title":"The effectiveness of tyrosine kinase inhibitors and molecular monitoring patterns in newly diagnosed patients with chronic myeloid leukemia in the community setting","volume":"15","author":"Di Bella","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"January 1","key":"10.1016\/j.leukres.2016.10.005_bib0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.23864","article-title":"ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?","volume":"90","author":"Etienne","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"June 3","key":"10.1016\/j.leukres.2016.10.005_bib0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"April 4","key":"10.1016\/j.leukres.2016.10.005_bib0130","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.leukres.2015.01.011","article-title":"Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia","volume":"39","author":"Lee","year":"2015","journal-title":"Leuk. Res."},{"issue":"December 4","key":"10.1016\/j.leukres.2016.10.005_bib0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hon.2005","article-title":"Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC","volume":"30","author":"Koren-Michowitz","year":"2012","journal-title":"Hematol. Oncol."},{"issue":"August 8","key":"10.1016\/j.leukres.2016.10.005_bib0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12032-015-0665-0","article-title":"Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1year in chronic myeloid leukemia patients treated with imatinib","volume":"32","author":"Francis","year":"2015","journal-title":"Med. Oncol."},{"issue":"June 24","key":"10.1016\/j.leukres.2016.10.005_bib0145","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"October 28","key":"10.1016\/j.leukres.2016.10.005_bib0150","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"September 3","key":"10.1016\/j.leukres.2016.10.005_bib0155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.beha.2009.04.005","article-title":"Prognostic factors in chronic myeloid leukaemia","volume":"22","author":"Hern\u00e1ndez-Boluda","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"October 29","key":"10.1016\/j.leukres.2016.10.005_bib0160","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2011.37.6962","article-title":"European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation","volume":"29","author":"Marin","year":"2011","journal-title":"J Clin Oncol."},{"issue":"December 26","key":"10.1016\/j.leukres.2016.10.005_bib0165","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"SPIRIT investigators; France intergroupe des leuc\u00e9mies my\u00e9lo\u00efdes chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"September 118(12)","key":"10.1016\/j.leukres.2016.10.005_bib0170","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"22","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"April Suppl. 2","key":"10.1016\/j.leukres.2016.10.005_bib0175","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML","volume":"94","author":"Talpaz","year":"2015","journal-title":"Ann. Hematol."},{"issue":"January 2","key":"10.1016\/j.leukres.2016.10.005_bib0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2010.10.018","article-title":"Imatinib treatment in chronic myelogenous leukemia: what have we learned so far?","volume":"300","author":"Breccia","year":"2011","journal-title":"Cancer Lett."},{"issue":"October 10","key":"10.1016\/j.leukres.2016.10.005_bib0185","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/leu.2015.170","article-title":"OCT1 and imatinib transport in CML: is it clinically relevant?","volume":"29","author":"Watkins","year":"2015","journal-title":"Leukemia"},{"issue":"February 2","key":"10.1016\/j.leukres.2016.10.005_bib0190","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"September 3","key":"10.1016\/j.leukres.2016.10.005_bib0195","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12185-011-0924-6","article-title":"The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia","volume":"94","author":"Razga","year":"2011","journal-title":"Int. J. Hematol."},{"issue":"March 3","key":"10.1016\/j.leukres.2016.10.005_bib0200","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12032-014-0851-5","article-title":"Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia","volume":"31","author":"de Lima","year":"2014","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2016.10.005_bib0205","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000336610","article-title":"Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia","volume":"127","author":"Nardinelli","year":"2012","journal-title":"Acta Haematol."},{"issue":"May 14","key":"10.1016\/j.leukres.2016.10.005_bib0210","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"July 2","key":"10.1016\/j.leukres.2016.10.005_bib0215","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2016.10.005_bib0220","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/07357907.2015.1065499","article-title":"Latin american leukemia net (LALNET). BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival","volume":"33","author":"Pagnano","year":"2015","journal-title":"Cancer Invest."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T17:52:09Z","timestamp":1601142729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616302168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":44,"alternative-id":["S0145212616302168"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.10.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}